A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.
Sheila F LumleyMarion DelphinJolynne F MokayaCedric C S TanEmily MartynMotswedi AndersonKa Chun LiElizabeth WaddiloveGloria SukaliLouise O DownsKhadija SaidDorcas OkandaCori CampbellEli HarrissYusuke ShimakawaPhilippa C MatthewsPublished in: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2024)
We have generated the first pooled estimates of HBV entecavir and tenofovir resistance over time. HBV resistance to entecavir in treatment-experienced groups in particular may represent a clinical and public health challenge. To date, tenofovir appears to have an excellent resistance profile, but due to data gaps, we caution that existing studies under-estimate the true real-world risk of resistance. Robust prospective data collection is crucial to reduce health inequities and reduce blind-spots in surveillance as treatment is rolled out more widely.